-
公开(公告)号：US11564975B2
公开(公告)日：2023-01-31
申请号：US17269874
申请日：2019-08-19
发明人： Jorge Amador Berlanga Acosta , Gerardo Enrique Guillén Nieto , Diana Garcia Del Barco Herrera , Francisco Hernández Bernal , Sonia Gonzalez Blanco , Raimundo Ubieta Gómez
摘要： The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.
-
公开(公告)号：US20210252109A1
公开(公告)日：2021-08-19
申请号：US17269874
申请日：2019-08-19
发明人： Jorge Amador BERLANGA ACOSTA , Gerardo Enrique GUILLÉN NIETO , Diana GARCIA DEL BARCO HERRERA , Francisco HERNÁNDEZ BERNAL , Sonia GONZALEZ BLANCO , Raimundo UBIETA GÓMEZ
摘要： The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.
-
公开(公告)号：US20210196793A1
公开(公告)日：2021-07-01
申请号：US17269788
申请日：2019-08-16
发明人： Diana GARCIA DEL BARCO HERRERA , Gerardo Enrique GUILLÉN NIETO , Mariela VAZQUEZ CASTILLO , Francisco HERNÁNDEZ BERNAL , Tatiana ZALDIVAR VAILLANT , Pablo Arsenio DIAZ REYES , ldania Caridad BALADRON CASTRILLO , Vladimir Armando BESADA PÉREZ , Sonia GONZALEZ BLANCO , Jorge Amador BERLANGA ACOSTA , Héctor Manuel PÉREZ SAAD
摘要： The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The efficacy of the pharmaceutical combination has a broad therapeutic window: it is independent of whether the pharmacological intervention occurs in the first or further hours after the brain damage, which broadens the therapeutic window.
-
公开(公告)号：US09717776B2
公开(公告)日：2017-08-01
申请号：US14418511
申请日：2013-08-02
申请人： Centro de Ingeniería Genética y Biotecnología , Consejo Superior de Investigaciones Cientificas
发明人： Héctor Jesús Santana Milián , Leonor Ventosa Rull , Eduardo Martínez Díaz , Jorge Amador Berlanga Acosta , Ingrid Cabrera Puig , Jaume Veciana Miró
IPC分类号： A61Q19/08 , A61K8/14 , A61K8/64 , A61K9/127 , A61K38/18 , A61K47/18 , A61K47/28 , A61K8/41 , A61K8/63 , A61K9/00 , A61L26/00
CPC分类号： A61K38/1808 , A61K8/14 , A61K8/416 , A61K8/63 , A61K8/64 , A61K9/0014 , A61K9/127 , A61K9/1271 , A61K9/1277 , A61K47/186 , A61K47/28 , A61K2800/805 , A61L26/0066 , A61L2300/414 , A61Q19/08
摘要： The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.
-
5.发明授权Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs 有权用于治疗和/或耐药肿瘤对抗癌药物的化学敏化的药物组合公开(公告)号：US08871725B2
公开(公告)日：2014-10-28
申请号：US12280629
申请日：2007-02-28
申请人： Silvio Ernesto Perea Rodriguez , Yasser Perera Negrin , Arielis Rodriguez Ulloa , Jeovanis Gil Valdés , Yassel Ramos Gómez , Lila Rosa Castellanos Serra , Lázaro Hiram Betancourt Núñez , Aniel Sánchez Puente , Jorge Fernández de Cossio Dorta Duque , Boris Ernesto Acevedo Castro , Luis Javier González López , Vladimir Besada Pérez , Daniel Fernando Alonso , Daniel Eduardo Gomez
发明人： Silvio Ernesto Perea Rodriguez , Yasser Perera Negrin , Arielis Rodriguez Ulloa , Jeovanis Gil Valdés , Yassel Ramos Gómez , Lila Rosa Castellanos Serra , Lázaro Hiram Betancourt Núñez , Aniel Sánchez Puente , Jorge Fernández de Cossio Dorta Duque , Boris Ernesto Acevedo Castro , Luis Javier González López , Vladimir Besada Pérez , Daniel Fernando Alonso , Daniel Eduardo Gomez
CPC分类号： A61K38/08 , A61K31/136 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/475 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/555 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7076 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.
摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，mitomicin C，伊马替尼，iressa和velcade（vortezomib）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。
-
公开(公告)号：US20240350611A1
公开(公告)日：2024-10-24
申请号：US18292237
申请日：2022-07-28
发明人： Iris VALDES PRADO , Lázaro GIL GONZÁLEZ , Laura LAZO VAZQUEZ , Lisset HERMIDA CRUZ , Gerardo Enrique GUILLEN NIETO , Karem COBAS ACOSTA , Yaremis ROMERO FERNÁNDEZ , Andy Jesús BRUNO DARDER , Edith SUZARTE PORTAL , Yusleidi de la Caridad PÉREZ FUENTES
IPC分类号： A61K39/12 , A61K39/00 , A61P37/04 , C07K14/005
CPC分类号： A61K39/12 , A61P37/04 , C07K14/005 , A61K2039/545 , A61K2039/55505
摘要： Recombinant chimeric antigen containing a polypeptide comprises amino acids 2 to 104 of the zika virus capsid protein or a polypeptide with an amino acid sequence with at least 90% identity with such capsid protein region. Vaccine composition that comprises such recombinant chimeric antigen and a pharmaceutically approved adjuvant. Use of the recombinant chimeric antigen containing a polypeptide comprises amino acids 2 to 104 of the zika virus capsid protein or a polypeptide with an amino acid sequence with at least 90% identity with such capsid protein region, for manufacturing a medicament for the induction of immune response against zika virus. The invention revels also a method for the induction of immune response against zika virus wherein this recombinant chimeric antigen is administered.
-
7.发明公开公开(公告)号：US20240317827A1
公开(公告)日：2024-09-26
申请号：US18578001
申请日：2022-07-07
发明人： Yordanka MASFORROL GONZÁLEZ , Hilda Elisa GARAY PÉREZ , Osvaldo REYES ACOSTA , Yasser PERERA NEGRÍN , Evelin CABALLERO MENÉNDEZ , Luis Javier GONZÁLEZ LÓPEZ , Vladimir Armando BESADA PÉREZ , Silvio Ernesto PEREA RODRÍGUEZ , Gerardo Enrique GUILLÉN NIETO , Sonia GONZÁLEZ BLANCO
CPC分类号： C07K14/4703 , A61P35/00 , A61K38/00 , C07K2319/10
摘要： Linear peptides that inhibit the phosphorylation mediated by the enzyme Casein Kinase 2 (CK2), which have an amino acid sequence selected from the group consisting of the sequences identified as SEQ ID NO: 45, SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 57-SEQ ID NO: 62, as well as polypeptides comprising said peptides and an intracellular penetrating peptide. A pharmaceutical composition comprising at least one of these linear peptides or polypeptides and a pharmaceutically acceptable carrier. The invention also discloses the use of said peptides or polypeptides for the manufacture of a drug, and a method of treating solid or liquid tumors where said drug is administered.
-
公开(公告)号：US11759517B2
公开(公告)日：2023-09-19
申请号：US17689581
申请日：2022-03-08
发明人： Julio César Aguilar Rubido , Yadira Lobaina Mato , Enrique Iglesias Perez , Eduardo Pentón Arias , Gerardo Enrique Guillén Nieto , Jorge Agustin Aguiar Santiago , Sonia Gonzalez Blanco , Jorge Valdes Hernandez , Mariela Vazquez Catillo
CPC分类号： A61K39/292 , A61K39/39 , A61P31/20 , A61K2039/5258 , A61K2039/543 , A61K2039/555 , A61K2039/575
摘要： This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
-
公开(公告)号：US20220272986A1
公开(公告)日：2022-09-01
申请号：US17631843
申请日：2020-07-30
发明人： Irene María ALVAREZ LUGO , Ileana SANCHEZ ORTIZ , Idania WONG PADILLA , Danalay SOMONTES SANCHEZ , Rolando MORAN VALDIVIA , Liszoe GALDÓS BETARTEZ , Laritza Caridad DOMINGUEZ RABILERO , Aylin NORDELO VALDIVIA
摘要： Biopesticide and biofertilizer composition comprising Pseudoxanthomonas indica, or metabolites from said bacterium, and excipients or diluents. Use of Pseudoxanthomonas indica, or metabolites from said bacterium to develop a biopesticide or biofertilizer composition. Method for the control of phytopathogens and zoonematodes comprising the administration of an effective amount of Pseudoxanthomonas indica, or its metabolites, to the plant or animal in need thereof. Method for the stimulation of plant growth comprising the administration of an effective amount of Pseudoxanthomonas indica, or metabolites from that bacterium, to the soil or substrate, plant or seed.
-
公开(公告)号：US20220259300A1
公开(公告)日：2022-08-18
申请号：US17531914
申请日：2021-11-22
摘要： Vaccine composition containing a mutant of the human Interleukin-15 (IL-15). The use of said mutant polypeptide of human IL-15 to manufacture a medicament for the active immunotherapy of diseases associated with IL-15 overexpression, including some autoimmune diseases and hematological malignancies. Administration to an individual that needs it of a therapeutically effective amount of the vaccine, that comprises the mutant polypeptide of the human IL-15 of the invention, constitutes a method for the therapy of IL-15 over-expressing related diseases.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.02 秒)
